These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17636923)

  • 1. New insight into the mechanism of action of and resistance to isoniazid: interaction of Mycobacterium tuberculosis enoyl-ACP reductase with INH-NADP.
    Argyrou A; Vetting MW; Blanchard JS
    J Am Chem Soc; 2007 Aug; 129(31):9582-3. PubMed ID: 17636923
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
    Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
    Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
    Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
    Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.
    Lu XY; You QD; Chen YD
    Mini Rev Med Chem; 2010 Mar; 10(3):181-92. PubMed ID: 20408801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.
    Slayden RA; Lee RE; Barry CE
    Mol Microbiol; 2000 Nov; 38(3):514-25. PubMed ID: 11069675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
    Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
    Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of epigallocatechin gallate and triclosan on enoyl-ACP reductase of Mycobacterium tuberculosis.
    Sharma SK; Kumar G; Kapoor M; Surolia A
    Biochem Biophys Res Commun; 2008 Mar; 368(1):12-7. PubMed ID: 17996734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.
    Holas O; Ondrejcek P; Dolezal M
    J Enzyme Inhib Med Chem; 2015; 30(4):629-48. PubMed ID: 25383419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
    Delaine T; Bernardes-Génisson V; Quémard A; Constant P; Meunier B; Bernadou J
    Eur J Med Chem; 2010 Oct; 45(10):4554-61. PubMed ID: 20696503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors.
    da Silva Lima CH; de Alencastro RB; Kaiser CR; de Souza MV; Rodrigues CR; Albuquerque MG
    Int J Mol Sci; 2015 Oct; 16(10):23695-722. PubMed ID: 26457706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.